Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Total Debt (2019 - 2026)

Opus Genetics has reported Total Debt over the past 5 years, most recently at $1.2 million for Q1 2026.

  • Quarterly Total Debt fell 90.58% to $1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Mar 2026, down 90.58% year-over-year, with the annual reading at $1.1 million for FY2025, N/A changed from the prior year.
  • Total Debt was $1.2 million for Q1 2026 at Opus Genetics, up from $1.1 million in the prior quarter.
  • Over five years, Total Debt peaked at $22.4 million in Q3 2025 and troughed at $93000.0 in Q3 2023.
  • The 4-year median for Total Debt is $1.2 million (2026), against an average of $7.2 million.
  • The largest YoY upside for Total Debt was 90.58% in 2026 against a maximum downside of 90.58% in 2026.
  • A 4-year view of Total Debt shows it stood at $215000.0 in 2022, then tumbled by 56.74% to $93000.0 in 2023, then surged by 1113.98% to $1.1 million in 2025, then increased by 6.11% to $1.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Total Debt are $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $22.4 million (Q3 2025).